<DOC>
	<DOCNO>NCT02593773</DOCNO>
	<brief_summary>The purpose phase 3 multi-center , open-label extension study evaluate long-term safety ACTIMMUNE® ( interferon-γ 1b ) subject Friedreich 's Ataxia ( FA ) .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy ACTIMMUNE Dose Escalation Friedreich 's Ataxia Study</brief_title>
	<detailed_description>Subjects complete 26 week blind treatment HZNP-ACT-301 , ( NCT02415127 ) eligible enter 6-month study . All subject choose participate receive ACTIMMUNE three time week ( TIW ) 26 week . In order maintain study blind HZNP-ACT-301 , subject open-label extension study undergo ACTIMMUNE titration , regardless receive ACTIMMUNE placebo HZNP-ACT-301.The Week 26 Visit HZNP-ACT-301 serve Baseline Visit ( Day 1 ) study . The study drug dose plan escalated weekly basis first 4 week treatment ( 10 µg/m2 100 µg/m2 ) , however , dose may reduce , interrupt , hold base tolerability . During treatment period , additional clinic visit schedule Weeks 4 , 13 , 26 ; clinic visit , subject ( and/or caregiver ) monitor via emails/phone call weekly basis subject reach maximum tolerated dose monthly basis thereafter .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Written inform consent child assent , applicable . Completed 26 week blind treatment Study HZNPACT301 , ( NCT02415127 ) . If female , subject pregnant lactating intend become pregnant study , within 30 day last dose study drug . Female subject childbearing potential must negative urine pregnancy test result Baseline/Day 1 ( Week 26 Study HZNPACT301 ) , agree use reliable method contraception throughout study 30 day last dose study drug . Subjects ineligible , opinion Investigator , unlikely comply study protocol concomitant disease condition could interfere conduct study potentially put subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Interferon gamma</keyword>
</DOC>